Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10663507 | 0.89 | L3MBTL1 (0.58) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL674671 | 0.89 | — | — | |
| SCHEMBL12141609 | 0.88 | L3MBTL1 (0.60) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL23471439 | 0.86 | L3MBTL1 (0.69) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL24745090 | 0.85 | CHRNB2 (0.48) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL26031379 | 0.85 | HSD11B1 (0.57) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL23471191 | 0.84 | GNAI3 (0.67) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL9633853 | 0.84 | GNAI3 (0.67) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL14595379 | 0.83 | HSD11B1 (0.56) | HSD11B1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL771426 | 0.83 | HSD11B1 (0.56) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242597-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170114323-A1 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | HSD11B1 2995/4885ALDH1A1 4698/4885L3MBTL1 3356/4885 |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | HSD11B1 2932/4885ALDH1A1 4564/4885L3MBTL1 2475/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | HSD11B1 1743/4885ALDH1A1 3615/4885L3MBTL1 4058/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | HSD11B1 2467/4885ALDH1A1 3241/4885L3MBTL1 1495/4885 |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | HSD11B1 43/4885ALDH1A1 295/4885L3MBTL1 4793/4885 |
| US-20170348320-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | HSD11B1 2188/4885ALDH1A1 3704/4885L3MBTL1 2914/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | HSD11B1 4668/4885ALDH1A1 3405/4885L3MBTL1 3422/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | HSD11B1 2995/4885ALDH1A1 4698/4885L3MBTL1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.